← Back to Search

Anti-cancer agent

Chemotherapy + Photodynamic Therapy for Cutaneous T-Cell Lymphoma

Phase 2
Waitlist Available
Research Sponsored by Millennix
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18 and over
No prior uncontrolled hyperlipidemia
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is studying bexarotene and photodynamic therapy to see how well they work compared with photodynamic therapy alone in treating patients with cutaneous T-cell lymphoma.

Who is the study for?
Adults diagnosed with early-stage cutaneous T-cell lymphoma (stage IB or IIA) within the last year can join this trial. They must have normal blood counts, liver and kidney function, not be pregnant or nursing, use effective contraception if fertile, test negative for HIV, and have no history of certain light-sensitive diseases or severe allergies to specific drugs.Check my eligibility
What is being tested?
The trial is testing how well a combination of chemotherapy drug bexarotene at different doses works with photodynamic therapy in treating patients. Photodynamic therapy involves using light-sensitive drugs that activate under light to kill cancer cells.See study design
What are the potential side effects?
Potential side effects may include reactions to the photosensitizing drug such as skin sensitivity to light, typical chemotherapy-related issues like nausea and fatigue, changes in blood counts leading to increased infection risk, and possible liver or kidney function alterations.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have never had uncontrolled high cholesterol.
Select...
I have never had pancreatitis or high risk for it.
Select...
My cancer has never been more advanced than stage IIA.
Select...
I have never had melanoma or invasive squamous cell carcinoma.
Select...
My skin cancer was confirmed as T-cell lymphoma in the last year.
Select...
I do not have a history of conditions like lupus, porphyria, albinism, or missing eye lenses.
Select...
I do not have any gallbladder diseases.
Select...
My cancer is at an early stage (Stage IB or IIA).

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

MillennixLead Sponsor
Joan Guitart, MDStudy ChairRobert H. Lurie Cancer Center
3 Previous Clinical Trials
72 Total Patients Enrolled
1 Trials studying Lymphoma
18 Patients Enrolled for Lymphoma

Media Library

Bexarotene (Anti-cancer agent) Clinical Trial Eligibility Overview. Trial Name: NCT00030589 — Phase 2
Lymphoma Research Study Groups:
Lymphoma Clinical Trial 2023: Bexarotene Highlights & Side Effects. Trial Name: NCT00030589 — Phase 2
Bexarotene (Anti-cancer agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00030589 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can individuals participate in this ongoing research?

"Reportedly, clinicaltrials.gov has documented that this experiment is no longer actively looking for participants; its last edit was on December 17th 2013. Despite this study's inactivity, there are still over 1700 other medical trials accepting patients at the present moment."

Answered by AI

How many medical facilities are offering this clinical trial to participants?

"This clinical trial is currently enrolling participants from a variety of sites, including H. Lee Moffitt Cancer Center and Research Institute in Tampa, University of Colorado Health Science Center in Aurora, and the University of Alabama at Birmingham Comprehensive Cancer Center in Birmingham. An additional 19 medical centres are also partaking in this research study."

Answered by AI

What possible adverse effects can arise from this treatment regimen?

"Due to the Phase 2 trial status of this treatment, our team at Power cautiously assigned it a score of 2 on the safety scale. This is partially based on supporting data for its security but no evidence regarding its efficacy yet."

Answered by AI
~15 spots leftby Mar 2025